D
URING the last decade considerable progress has been made in our understanding of the mechanisms by which hormones and neurotransmitters act through specific receptors to elicit biochemical and physiological responses in their target tissues. Many of these data have come as a result of the development of ligand binding techniques. These techniques have provided investigators with the ability to identify and quantitate receptors. In addition, they have permitted correlation of the pharmacological properties of these receptors with the properties of the biochemical or physiological responses elicited by these hormones or neurotransmitters. In the adrenergic systems, the properties of j 8 r and /3 2 -adrenergic receptor subtypes have been found to correlate well with the ability of catecholamines to stimulate adenylate cyclase in numerous tissues.
1 -2 Binding of ligands to the a 2 -adrenergic receptors has been shown to correlate with the ability of catecholamines to inhibit stimulation of adenylate cyclase in certain tissues. 3 -4 Binding of ligands to «,-adrenergic receptors in liver and vascular smooth muscle has been shown to correlate with the physiological effects of catecholamines on these tissues. The exact biochemical mechanisms involved in the signal transfer for this receptor, however, have not been entirely elucidated, although changes in cellular calcium and membrane phospholipid metabolism
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have been implicated. 5 6 Because these various receptor subtypes all bind the same catecholamines, the question of whether a-and /3-adrenergic receptors are structurally related molecules has been of long-standing interest in the field of adrenergic pharmacology. Until recently, however, the molecular characteristics of these receptors had not been examined.
Several approaches lend themselves to the biochemical characterization of receptors. Because receptors bind ligands with a high degree of specificity and selectivity, they represent ideal proteins to be purified by affinity chromatography. Moreover, because of this specificity and high affinity of binding, specific affinity and photoaffinity probes can be designed by which the receptors can be covalently tagged and identified. Finally, the availability of purified preparations of receptor should allow the development of antibodies against the purified proteins for use in the further characterization of the receptors.
In fact, these approaches have proved successful in the characterization of the adrenergic receptors from various sources. Affinity chromatography procedures for the purification of /3,-, /3 2 -, a,-, and a 2 -adrenergic receptors have been reported.
7 " 10 With these procedures the /3-adrenergic receptor from several tissues has been purified to apparent homogeneity."" 14 Similarly, purification of the a,-adrenergic receptor from rat liver plasma membranes also has been reported 10 with affinity chromatography. Moreover, high-affinity, high-specific-radioactivity, photoaffinity probes specific for a,-and /3-adrenergic receptors have been developed. I5~M The availability of purified /3-adrenergic receptor preparations has led recently to the development of antibodies against the frog erythrocyte /3-adrenergic receptor. 21 These results underscore the feasibility of using the various approaches just described in the characterization of the various receptors for catecholamines.
Although these procedures have been developed for the characterization of the various catecholamine receptors, the original studies were done almost exclusively with peripheral tissues. Very little information is actually available on the molecular characteristics of these receptors in the central nervous system. In this paper we will attempt to compare the subunit structure of a,-and /3-adrenergic receptors of the brain with that of peripheral tissues as revealed by photoaffinity labeling. In addition, we will show that by using anti-/3-adrenergic receptor antibodies and immunocytochemistry, the /3-adrenergic receptor of the brain can be localized in postsynaptic clusters.
Identification of Adrenergic Receptors in Rat
Brain by Photoaffinity Labeling Visualization of receptors for hormones and neurotransmitters in tissue or crude membrane preparations is a complex problem as receptors are present in the plasma membrane in very low concentration. Thus, for a potential receptor probe to be usable it should: (1) have high affinity and selectivity for the receptor site, (2) be labeled to high-specific radioactivity (preferably with iodine), and (3) have a suitable chemically reactive group capable of incorporating into a polypeptide chain. The photoaffinity probes that have been developed recently for the labeling of a,-and /3-adrenergic receptors all possess these properties. Thus, it has become possible to identify receptors in crude membrane preparations even in the absence of any purification of the receptors themselves.
In the central nervous system, the four subtypes of receptors for catecholamines have been demonstrated by ligand binding 22 " 24 and autoradiography. 23 -M Little information is available, however, about the molecular structures of these receptors. Thus, we have used the a,-and /3-adrenergic photoaffinity probes developed in our laboratories: 4-amino-6,7-dimethoxy-2[4(5(3- l25 I]pABC, to attempt to probe the structure of these receptors in the brain.
Labeling of the /3-Adrenergic Receptors
Membranes from rat cerebellum and cortex were prepared in the following manner. Brains were removed and bathed in ice-cold 0.32 M sucrose, 1 mM EDTA. Cerebellum and cerebral cortex were dissected out and homogenized in 20 volumes of ice-cold 0.32 M sucrose, 1 mM EDTA in a glass teflon homogenizer. The homogenate was centrifuged at 500 g for 10 minutes at 0° C to 4° C (Sorvall SS-34 rotor, Ivan Sorvall, Inc., Norwalk, CT). The supernatant was recentrifuged at 12,000 g for 20 minutes. The pellet obtained was discarded and the supernatant centrifuged at 158,000 g for 45 minutes (Beckman Ti-45; Beckman Instruments, Fullerton, CA). The resulting pellet (membrane fraction) was washed twice by centrifugation at 40,000 g for 15 minutes with 150 mM NaCl, 5 mM EDTA, 50 mM Tris-hydrochloride (pH 7.5), resuspended in the same buffer, and stored at -8 0°C until used.
Membranes (2-3 mg of protein; equivalent to 400-600 fmol of /3-adrenergic receptor) were incubated in 50-ml polycarbonate tubes in a total volume of 25 ml (16-24 pM receptor concentration) for 90 minutes at 25° C with 50 to 100 pM [ 125 I]pABC under dim light in the presence and absence of 10 /xM alprenolol. The membranes were washed by centrifugation at 40,000 g for 15 minutes in cold incubation buffer that contained 0.5% bovine serum albumin (essentially fatty-acid free), resuspended in 15 ml of bovine-serum-albuminfree buffer, and photolyzed. Labeled membranes were dissolved in 10% sodium dodecyl sulfate, 10% glycerol, 5% /3-mercaptoethanol, 25 mM Tris-hydrochloride (pH 6.8) and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmli. 27 After the electrophoresis the gels were dried and exposed at -70° C for 1 to 3 days with Kodak XAR film (Kodak, Rochester, N.Y.) with intensifying screens (Lightning Plus; du Pont Co., Wilmington, DE); the films were developed manually according to Kodak instructions. As shown in Figure 1 , when a microsomal preparation of either rat cerebellum or cerebral cortex was incubated with the antagonist ['"I]pABC a peptide with a molecular weight of 60,000 was labeled, as revealed by SDS-PAGE autoradiography of the membrane samples. 19 The covalent labeling of this band was blocked by the presence of 10 /u.M alprenolol in the membrane incubation. Because the cerebellum contains almost exclusively /3 2 -adrenergic receptors 28 and cerebral cortex contains predominantly /3,-receptors, 29 it is reasonable to suggest that the peptides labeled by [ l2i I]pABC represent respectively the /3 2 -and /3,-adrenergic receptors in these two regions of the brain. The peptides labeled in the brain by the photoaffinity probe [ l25 I]pABC seem to have molecular weights similar to the y3-adrenergic receptor peptides identified or purified from peripheral tissues. Recent studies have shown that the cardiac /3,-adrenergic receptor binding site of many species (including humans) resides on a peptide with a molecular weight of 62,000, M while the )3 2 -adrenergic receptor from mammalian lung has been characterized as a peptide with a molecular weight of 64,000.™-i2 Determination of the extent of homology among the receptor peptides from different tissues or from the two different subtypes will have to await further characterization of these proteins.
Labeling of the a i -Adrenergic Receptor Membranes were prepared as described in the previous section. Membranes (2-3 mg of protein, 400-600 fmol of total receptor) were then incubated for 90 minutes at 25° C with 50 to 100 pM [
123 I]APDQ in a total volume of 25 ml in the dark alone or with prazosin 10 /iM; phentolamine, 10 /nM; yohimbine, 10 /i.M, (-)epinephrine, 30 /AM; ( + )epinephrine, 30 FIM; ( -)norepinephrine, 30 /A.M; or (-)isoproterenol 30 /LAM, washed, and photolyzed as described previously. 19 Other conditions were as described in the previous section.
As shown in Figure 2 , incubation of a cerebral cortex microsomal preparation that is rich in a,-adrenergic receptors with the a,-adrenergic photoaffinity probe 
(-)Epi = (-)epinephrine; (+ )Epi = ( + )epinephrine; (-)NE = (-)norepinephnne; (-)iso = (-)isoproterenol.
ular weight of 79,000. As can be seen in Figure 2 incorporation of this high-affinity probe also can be observed in lower-molecular-weight peptides (54,000 and 42,000); however, only the peptide with a molecular weight of 79,000 was labeled with the appropriate specificity. Thus, at 0.1 piM concentrations, the a,-selective antagonist prazosin was much more potent than was the a 2 -selective agent yohimbine in blocking covalent incorporation of [ l2i I]APDQ. (-)Epinephrine and (-)norepinephrine were equally effective at 30 ( I M but (-)isoproterenol was ineffective. The ( + )isomer of epinephrine was slightly less potent than its ( -)isomer, as expected for an a,-adrenergic receptor. A similar peptide (M r = 80,000) has been identified by photoaffinity labeling of rat liver plasma membrane 15 as well as of several other tissues that contain a,-adrenergic receptors (Dickinson and Leeb-Lundberg, unpublished observations). Recently, Kunos et al. 33 have reported the identification of a peptide with a molecular weight of 80,000 with the properties of an a,-adrenergic binding site by covalently labeling rat liver plasma membranes with the alkylating agent [
3 H]-phenoxybenzamine. In this study, another peptide with a molecular weight of 58,000 also was labeled specifically but was thought to represent a proteolytically generated fragment from the larger receptor peptide. These data agree with our own findings in rat liver with [ 125 I]APDQ where similar lowermolecular-weight peptides could be evidenced." These peptides, which still contain an intact ligand binding site, may be similar to the peptide (M r = 59,000) purified by Graham et al. 10 from rat liver membranes with affinity chromatography.
Immunocytochemical Localization of /3-Adrenergic Receptors
As mentioned previously the presence of /3-adrenergic receptors in various regions of the brain was documented originally by ligand binding studies 22.28.29 p a i a c i o s a n j Kuhar 25 later confirmed and extended these findings by performing light microscopic autoradiographic localization of these receptors with radiolabeled antagonists; however, these techniques are of limited resolution and can only be used to map the regional distribution of these receptors in the brain. Although numerous studies that used biochemical fractionation techniques or selective neurotoxins have suggested that /3-adrenergic receptors in the brain may be associated with postsynaptic neurons (reviewed in 34 ), it previously has not been possible to test this hypothesis directly.
The availability of antibodies capable of specifically recognizing the /3-adrenergic receptor 21 has allowed the examination of its morphological localization. Immunocytochemical localization in frog and rat brain with the antibodies and secondary peroxidase-antiperoxidase staining revealed immunoreactivity in the cerebellum, hippocampus, and neostriatum, regions that have been shown by ligand binding 22 u or autoradiography 23 to be the areas where the /3-receptors are most concentrated. No labeling was detected in brain sections incubated with receptor-adsorbed antiserum or with preimmune serum. Moreover, in laminated regions of the cerebellar cortex, receptor immunoreactivity was localized in the outer molecular layer with concentrations in distal regions of Purkinje cell dendrites and dendritic spines but not in cell bodies. 21 Thus, at the light microscopic level, the distribution of /3-adrenergic receptor immunoreactivity was the same as the localization of /3-adrenergic receptors documented previously by other techniques. 21 To determine the localization of the receptors at a higher resolution, the specific immunoreactivity of the dendrites was examined at the electron microscopic level. Brain sections were prepared as described in Strader et al.
2 ' Adjacent sections were incubated at 4° C for 24 hours with antiserum to the receptor at a 1:100 dilution or with antiserum absorbed with partially purified receptor. The sections were then washed and treated sequentially with a 1:50 dilution of goat antirabbit immunoglobulin, a 1 MOO dilution of peroxidase-antiperoxidase, and 3,3'-diaminobenzidine-hydrogen peroxide. Samples were prepared for electron microscopy and examined with a Philips 201 electron microscope (Philips Co., Gldeilampenfabriken-Eindhoven, The Netherlands). The results are taken from Strader et al. 21 Figure 3 shows sections of frog hippocampus and rat cerebellum. In frog hippocampus ( Figure 3A ) /3-adrenergic receptor immunoreactivity was observed through the cytoplasm of the cell and on the cell membrane. The highest concentration of receptor was located on regions of the membrane directly opposite the synaptic cleft (identified by the characteristic structure of presynaptic vesicles). In rat cerebellum ( Figure 3B ) a section of a Purkinje cell dendrite also revealed accumulations of receptor immunoreactivity in areas of synaptic contact. In larger fields the distribution of these postsynaptic clusters of receptor immunoreactivity was comparable to the distribution of specific catecholaminergic nerve terminals, as assessed by the immunolocalization of tyrosine hydroxylase. 21 Thus, in brain, /3-adrenergic receptors appear to be clustered at the postsynaptic junctions of adrenergic neurons. This finding represents the first demonstration of the localization of the /3-adrenergic receptor at the high resolution afforded by the electron microscope.
Discussion
Receptors for catecholamines are almost ubiquitous in the body as responsiveness to catecholamines can be demonstrated in virtually every tissue. Stimulation or blockade of these receptors is important in the therapy of many prevalent human illnesses. Thus, the mechanisms by which these receptors mediate their effects is of primary interest. To elucidate the complete mechanisms of action of these hormones/neurotransmitters, however, it will be essential eventually to characterize biochemically the receptors and their effector systems. As reviewed in this paper, methods are now becoming available to accomplish this endeavor for the various catecholamine receptors. Affinity chromatography and photoaffinity-labeling techniques have been developed for a-and /3-adrenergic receptors, 7 " 20 and /3,-, and /3,-, as well as a,-adrenergic receptors have been purified to apparent homogeneity. 10 " 14 As reported in this paper, with the technique of photoaffinity labeling it appears that /3,-and /3 2 -adrenergic receptor binding sites in the central nervous system reside on peptides of molecular weight similar to those peptides that have been identified or purified from peripheral tissues. Whether these peptides represent products from the same gene cannot be determined at this time; however, a recent study comparing mammalian peripheral / 3 r and /3 2 -receptors by peptide mapping of photoaffinity-labeled peptides suggest that /3,-and /3 2 -peptides, while having similar molecular weights, show significant differences. 35 The a,-adrenergic receptor of the cerebral cortex also appears to reside on a peptide of molecular weight (80,000) similar to that from peripheral tissues, as evidenced by photoaffinity labeling of a,-adrenergic receptors. In both brain and peripheral tissues a r and /3-adrenergic receptors appear to reside on peptides of completely different molecular weights (62,000-64,000 versus 80,000). Whether these a, and /3-adrenergic receptors show any degree of homology will have to await further structural characterization of the purified proteins.
As reviewed in this paper, the availability of an antibody to the frog erythrocyte /3 2 -adrenergic receptor has permitted immunocytochemical localization of /3-receptors in the brain. It has been demonstrated in both frog and rat brain that /3-adrenergic receptors are clustered at the postsynaptic junctions of adrenergic neurons.
